India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 - Growth Trends and Forecasts (2025-2032)
Select a License Type that Suits your Business Needs
US$ 2,000
Two thousand dollars
Single User License
(1 User)
US$ 4,500
US$ 3,000
Three thousand dollars
Frequently Purchased
Multi User License
(Upto 7 Users)
US$ 7,000
US$ 5,000
Five thousand dollars
Corporate User License
(Unlimited Users)
US$ 10,000
US$ 6,000
Six thousand dollars
Client Testimonials
Client Testimonials
Our Clients
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

860519526
9001:2015
27001:2022